Nitrofurantoin sodium

| Cat. No.: | HY-A0090A | | |
|--------------------|---|----------|--|
| CAS No.: | 54-87-5 | | |
| Molecular Formula: | C ₈ H ₆ N ₄ NaO ₅ | | |
| Molecular Weight: | 261.15 | | |
| Target: | Antibiotic; Bacterial | <u> </u> | |
| Pathway: | Anti-infection | No | |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. | Iva | |

| | TV | | | | |
|-------------|--|--|--------------|--|--|
| Description | Nitrofurantoin sodium is a potent and orally active antibacterial agent. Nitrofurantoin sodium acts as an antibiotic. Nitrofurantoin sodium can be used for the study of urinary tract infections (UTIs), including cystitis and kidney infections ^[1] | | | | |
| In Vitro | Nitrofurantoin sodium (0-512 mg/L; 8 h) treatment inhibits the growth of E. coli isolates ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[3] | | | | |
| | Cell Line: | E. coli isolates: DA10708, DA13815, DA13824, DA13957, DA13992, DA10626, DA10627 | | | |
| | Concentration: | 0, 32, 64, 128, 256, and 512 mg/L | | | |
| | Incubation Time: | 8 hours | | | |
| | Result: | Observed bactericidal effect at 32 mg/L For DA10708, DA13815 and DA13824. Inhibited the growth of DA13957 and DA13992 completely at 128 mg/L, observed bactericidal effect at 256 mg/L. Showed a moderate killing at >128 mg/L for DA10626 and DA10627. | | | |
| In Vivo | Nitrofurantoin pharmacokinetic effects in SD Rats ^[4] . | | | | |
| | Parameters 10 | mg/kg p.o. | 2 mg/kg i.v. | | |
| | AUC ₀₋₇₂₀ (μg/mL•min) | 306 | | | |
| | AUC ₀₋₁₂₀ (μg/mL•min) | | 90.3 | | |
| | AUC _{0-∞} (µg/mL•min) | 344 | 91.5 | | |
| | C _{max} (μg/mL) | 1.01 | | | |

Product Data Sheet

| CL/F or CL (ml/min/kg) | 31.0 | 22.7 |
|------------------------|------|------|
| t _{1/2} (min) | 166 | 23.6 |
| Bioavailability (%) | 60.1 | |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2022 Mar 2;13(1):1116.
- Water Res. 2023 May 21, 120110.
- Biotechnol Bioeng. 2021 Sep 3.
- Microbiol Spectr. 2022 Jan 12;e0099121.
- Research Square Preprint. 2021 Aug.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Huttner A, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64.

[2]. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202.

[3]. Linus Sandegren, et al. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother. 2008 Sep;62(3):495-503.

[4]. Xiaodong Wang, et al. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos. 2007 Feb;35(2):268-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA